(Information is sent by the signing entity:)
· This program is part of the Seegene OneSystemTM business, which aims to create a “world free of all diseases.”
· Seegene will collaborate with clinical researchers around the world to share its technology and enable researchers to develop syndromic qPCR tests.
SIGINI (KQ096530), a leading Korean company providing complete solutions for PCR molecular diagnostics, today launched its “Open Innovation Plan” Partner with Springer Nature, a leading global service provider to the research community. Launched globally, this first program represents the first step in supporting experts, scientists and clinicians in the development of syndromic quantitative PCR (qPCR) tests in all fields.
The “Open Innovation Initiative” is part of the Seegene OneSystemTM business model, which aims to create a world free of all diseases by developing diagnostic and early diagnosis products in all fields, including cancer and infectious diseases, and even with applications in other biological fields. world. All living things except humans.To achieve this goal, Seegene OneSystemTM will share Technology and experience The company’s 20-plus-year relationships with global partners will enable scientists around the world to develop new diagnostic products for a variety of diseases.
The launch phase of the Open Innovation Initiative includes 15 projects develop 15 diagnostic tests Detect a wide range of infectious diseases, including vector-borne diseases, and detect drug-resistant pathogens by qPCR. Applications can be submitted until 31 October 2023 (11.59 pmx`x` GMT) and, following a thorough assessment of applications, the successful bidder will be announced on 15 March 2024. Applicants must be a team of two or more persons employed by or affiliated with a university, research institute, or similar organization authorized to conduct preclinical and clinical research. In addition to research grants of up to $600,000 per project, awardees will receive free Seegene Syndrome qPCR reagents, extraction reagents, consumables, clinical research methods education, and instrumentation and software to perform automated experiments. Support the conduct of preclinical and clinical studies related to the target pathogens identified during the study.
The 15 items are divided into the following categories: Urinary tract infections
- dermatophytes
- sexually transmitted infections
- Screening for vaginitis, including group B strep
- Respiratory Pathogens Group
- Typing of non-tuberculous mycobacteria
- tick-borne diseases
- Tropical diseases
- Methicillin-resistant Staphylococcus aureus
- multidrug-resistant microorganisms
Commenting on the format of the program, Dr. Dae-Hoon Lee, Executive Vice President and Head of Research and Development at Seegene, said: “As this is the first phase of the open innovation program, Seegene will lead the majority of the program’s efforts – including product design, product Development planning and feasibility studies without clinical samples – allowing the successful bidder to focus on conducting preclinical and clinical studies using clinical samples.
In the next phase, the winning bidder will use the Seegene Digital Development System (SGDDS) to execute the entire development plan, starting from Product design to clinical validation«.
The launch of the open innovation initiative follows Seegene’s announcement of a strategic alliance agreement with Springer Nature in June 2023. Under the agreement, Springer Nature demonstrates the Seegene OneSystem™ business model to the global scientific community to actively participate in the development of new assays. The global network covers all fields.
“We believe in Seegene’s mission to create a world free of disease by sharing its cutting-edge technology with the global scientific community,” said Richard Hughes, vice president of publishing, nature and impact solutions at Springer Nature ) said. “We invite scientists from diverse fields to collaborate with Seegene to develop PCR tests that can have a real impact on global health.”
PCR molecular diagnostics companies typically develop only a few syndromic testing By year. However, through its open innovation initiative, Seegene seeks to significantly increase the number of assays that can be developed each year to hundreds or even thousands.
“With this initiative, Seegene has taken a historic first step toward its goal of creating a ‘world free of all diseases,'” said Dr. Jong-Yoon Chun, CEO of Seegene. “The launch of our global program will not only accelerate Seegene’s The OneSystem™ business will also impact the widespread adoption of syndromic qPCR diagnostics.”
Seegene expands its Seegene OneSystem™ business model to create a “world free of all diseases.”
As part of the Seegene OneSystem™ business, Seegene recently signed alliance agreements with leading diagnostics companies: Israel’s Hylabs and Spain’s Werfen. Seegene plans to expand partnerships in European and Asian countries this year. By 2028, Seegene aims to have signed alliances with leading companies in 100 countries.
Seegene is committed to sharing syndromic qPCR detection technology through Seegene OneSystem™; automated detection development technology (SGDDS); standardized raw material technology; automated instrument technology (AIOS™); automated manufacturing technology (SG MATES&ARMS); and data analysis and information management technology ( SG STATS).
Starting today, more information about the open innovation initiative and its anticipated health benefits will be shared on the Springer Nature and Seegene websites.
Photo – https://mma.prnewswire.com/media/2201041/OpenInnovationProgram.jpg
Logo – https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg
SOURCE: Seegene Corporation